Drug Type Fusion protein |
Synonyms MariTide, AMG-133, AMG133 |
Target |
Mechanism GIPR antagonists(Gastric inhibitory polypeptide receptor antagonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Start Date25 Apr 2024 |
Sponsor / Collaborator |
Start Date03 Apr 2024 |
Sponsor / Collaborator Amgen, Inc. [+1] |
Start Date18 Jan 2023 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity | Phase 1 | US | 07 Aug 2020 | |
Overweight | IND Approval | CN | 20 Nov 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 75 | benydsupdl(qhqlhpunwg) = tyrgldyfyy plsyprhvpj (umuhvdjtzw ) | Positive | 07 Nov 2022 | |||
Placebo | benydsupdl(qhqlhpunwg) = dkiuogjnnw plsyprhvpj (umuhvdjtzw ) |